ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements related to the company's Iomab-B BLA application [3][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $75,000 in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [3]. - The complaint alleges that Actinium and its executives made false or misleading statements regarding the likelihood of FDA approval for the Iomab-B BLA, which could lead to significant investor losses [5]. Group 2: Stock Performance and Market Reaction - Following the revelation of the need for an additional clinical trial to support the BLA filing, Actinium's stock price dropped by $3.69, or nearly 60%, closing at $2.48 on August 5, 2024 [6][7]. - The decline in stock price was attributed to the market's reaction to the company's regulatory update, indicating that the initial data from the Sierra Trial was unlikely to meet FDA guidelines [5][6]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is typical of class members and oversees the litigation [8]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8].